Rifaquat Rahman, Diana D Shi, Zachary J Reitman, Petra Hamerlik, John F de Groot, Daphne A Haas-Kogan, Alan D D'Andrea, Erik P Sulman, Kirk Tanner, Nathalie Y R Agar, Jann N Sarkaria, Christopher L Tinkle, Ranjit S Bindra, Minesh P Mehta, Patrick Y Wen
{"title":"脑肿瘤中的 DNA 损伤反应:神经肿瘤学会关于神经肿瘤学机制和转化工作的共识综述。","authors":"Rifaquat Rahman, Diana D Shi, Zachary J Reitman, Petra Hamerlik, John F de Groot, Daphne A Haas-Kogan, Alan D D'Andrea, Erik P Sulman, Kirk Tanner, Nathalie Y R Agar, Jann N Sarkaria, Christopher L Tinkle, Ranjit S Bindra, Minesh P Mehta, Patrick Y Wen","doi":"10.1093/neuonc/noae072","DOIUrl":null,"url":null,"abstract":"<p><p>DNA damage response (DDR) mechanisms are critical to maintenance of overall genomic stability, and their dysfunction can contribute to oncogenesis. Significant advances in our understanding of DDR pathways have raised the possibility of developing therapies that exploit these processes. In this expert-driven consensus review, we examine mechanisms of response to DNA damage, progress in development of DDR inhibitors in IDH-wild-type glioblastoma and IDH-mutant gliomas, and other important considerations such as biomarker development, preclinical models, combination therapies, mechanisms of resistance and clinical trial design considerations.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300028/pdf/","citationCount":"0","resultStr":"{\"title\":\"DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.\",\"authors\":\"Rifaquat Rahman, Diana D Shi, Zachary J Reitman, Petra Hamerlik, John F de Groot, Daphne A Haas-Kogan, Alan D D'Andrea, Erik P Sulman, Kirk Tanner, Nathalie Y R Agar, Jann N Sarkaria, Christopher L Tinkle, Ranjit S Bindra, Minesh P Mehta, Patrick Y Wen\",\"doi\":\"10.1093/neuonc/noae072\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>DNA damage response (DDR) mechanisms are critical to maintenance of overall genomic stability, and their dysfunction can contribute to oncogenesis. Significant advances in our understanding of DDR pathways have raised the possibility of developing therapies that exploit these processes. In this expert-driven consensus review, we examine mechanisms of response to DNA damage, progress in development of DDR inhibitors in IDH-wild-type glioblastoma and IDH-mutant gliomas, and other important considerations such as biomarker development, preclinical models, combination therapies, mechanisms of resistance and clinical trial design considerations.</p>\",\"PeriodicalId\":19377,\"journal\":{\"name\":\"Neuro-oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2024-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300028/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/neuonc/noae072\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noae072","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
DNA 损伤应答(DDR)机制是维持基因组整体稳定性的关键,其功能障碍可导致肿瘤发生。我们对 DDR 途径的认识取得了重大进展,这为开发利用这些过程的疗法提供了可能。在这篇专家共识综述中,我们探讨了 DNA 损伤的反应机制、IDH 野生型胶质母细胞瘤和 IDH 突变型胶质瘤中 DDR 抑制剂的开发进展,以及生物标志物开发、临床前模型、联合疗法、耐药机制和临床试验设计注意事项等其他重要考虑因素。
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
DNA damage response (DDR) mechanisms are critical to maintenance of overall genomic stability, and their dysfunction can contribute to oncogenesis. Significant advances in our understanding of DDR pathways have raised the possibility of developing therapies that exploit these processes. In this expert-driven consensus review, we examine mechanisms of response to DNA damage, progress in development of DDR inhibitors in IDH-wild-type glioblastoma and IDH-mutant gliomas, and other important considerations such as biomarker development, preclinical models, combination therapies, mechanisms of resistance and clinical trial design considerations.
期刊介绍:
Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field.
The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.